Physician profile
Bhuvin Buddhdev
NPI 1881907681
$36,027.34
in general payments reported to CMS, 2019-2025
32 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $16.92 · 2021: $314 · 2022: $371 · 2023: $13K · 2024: $8,308 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $21K · Food and Beverage: $10K · Travel and Lodging: $3,992 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $20,915.00 |
| Food and Beverage | $10,006.84 |
| Travel and Lodging | $3,991.92 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $20,047.11 | 2020-2025 | Tyvaso, Remodulin, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $11,303.93 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Pfizer INC. | $1,000.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $535.18 | 2023-2025 | |
| Paragonix Technologies, INC. | $439.40 | 2024 | Sherpapak, Liverguard, Pancreaspak |
| Merck Sharp & Dohme LLC | $412.00 | 2019-2025 | Winrevair, Prevymis, Zerbaxa |
| Abbvie INC. | $300.86 | 2024-2025 | |
| Astellas Pharma US INC | $218.84 | 2019-2025 | Cresemba |
| Johnson & Johnson Health Care Systems INC. | $214.89 | 2024-2025 | Uptravi, Opsumit |
| Insmed, INC. | $211.94 | 2024-2025 | Arikayce, Brinsupri |
| Takeda Pharmaceuticals U.S.A., INC. | $189.43 | 2023-2025 | Livtencity, Glassia |
| Abbott Laboratories | $179.47 | 2023 | Mitraclip |
| Abiomed | $140.41 | 2025 | |
| Allergan, INC. | $126.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.46 | 2022-2025 | Ofev, Jascayd |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $73.12 | 2023-2025 | Treprostinil |
| Genzyme Corporation | $67.62 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $61.56 | 2021-2025 | Airsupra, Fasenra |
| Ani Pharmaceuticals, INC. | $51.50 | 2025 | Purified Cortrophin Gel |
| Medtronic, INC. | $45.61 | 2021 | |
| Glaxosmithkline, LLC. | $37.73 | 2025 | Nucala |
| Shionogi INC | $34.25 | 2024-2025 | Fetroja |
| Biomerieux INC | $32.58 | 2023 | Filmarray Pneumonia Panel (Pneumo) |
| Aimmune Therapeutics, INC. | $31.70 | 2025 | Zenpep |
| Vifor Pharma, INC. | $24.14 | 2024 | Zemaira |
| Invivyd INC | $21.90 | 2025 | Pemgarda |
| Shire North American Group INC | $21.11 | 2019 | |
| Verona Pharma, INC. | $20.84 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $17.37 | 2024 | Dupixent |
| Janssen Pharmaceuticals, INC | $17.18 | 2019 | |
| Philips North America LLC | $15.60 | 2025 | Vest Therapy Und |
| Breas Medical, INC. | $9.86 | 2025 | Vivo 45 Ls |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhuvin Buddhdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.